Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Addison, Christina L ^a,b   Pond, Gregory R ^c   Zhao, Huijun ^a   Mazzarello, Sasha ^a   Vandermeer, Lisa ^a   Goldstein, Robyn ^d   Amir, Eitan ^d   Clemons, Mark ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Biomarker; Bisphosphonate; Bone metastasis; Breast cancer; De escalated therapy; Skeletal related event

Indexed keywords

EID: 84933045557     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-577     Document Type: Article

References (43)

1. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M: A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Breast Cancer Res Treat 2014,144(3):615–624. doi:10.1007/s10549–014–2906-x 10.1007/s10549-014-2906-x
2. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI: Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.Lancet Oncol 2013,14(7):663–670. doi:10.1016/S1470–2045(13)70174–8 10.1016/S1470-2045(13)70174-8
3. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M: Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer.Am J Clin Oncol 2012. doi:10.1097/COC.0b013e3182568f7a
4. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M: Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.Am J Clin Oncol 2013,36(5):436–442. doi:10.1097/COC.0b013e3182568f7a 10.1097/COC.0b013e3182568f7a
5. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M: TGF-beta signalling-related markers in cancer patients with bone metastasis.Biomarkers 2008,13(2):217–236. doi:10.1080/13547500701676019 10.1080/13547500701676019
6. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cella D: Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.J Pain Symptom Manage 2009,38(2):244–257. doi:10.1016/j.jpainsymman.2008.08.005 10.1016/j.jpainsymman.2008.08.005
7. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE: Bone resorption predicts for skeletal complications in metastatic bone disease.Br J Cancer 2003,89(11):2031–2037. doi:10.1038/sj.bjc.6601437 10.1038/sj.bjc.6601437
8. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE: Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.Breast Cancer Res Treat 2010,123(3):767–779. doi:10.1007/s10549–010–0981–1 10.1007/s10549-010-0981-1
9. Chevrel G, Limouzin A, Garnero P, De Montalivet C, Loubier D: Fractures and handicap in an adult population: A clinical study.Joint Bone Spine 2007,74(6):584–589. doi:10.1016/j.jbspin.2007.01.039 10.1016/j.jbspin.2007.01.039
10. Clemens JD, Herrick MV, Singer FR, Eyre DR: Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.Clin Chem 1997,43(11):2058–2063.
11. Clemons M, Gelmon KA, Pritchard KI, Paterson AH: Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.Curr Oncol 2012,19(5):259–268. doi:10.3747/co.19.1011
12. Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent RA, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN: Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.Breast Cancer Res Treat 2014,146(1):153–162. doi:10.1007/s10549–014–3015–6 10.1007/s10549-014-3015-6
13. Coleman R: The use of bisphosphonates in cancer treatment.Ann N Y Acad Sci 2011, 1218:3–14. doi:10.1111/j.1749–6632.2010.05766.x 10.1111/j.1749-6632.2010.05766.x
14. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer.Br J Cancer 1987,55(1):61–66. 10.1038/bjc.1987.13
15. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.J Clin Oncol 2005,23(22):4925–4935. doi:10.1200/JCO.2005.06.091 10.1200/JCO.2005.06.091
16. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Cancer Treat Rev 2008,34(7):629–639. doi:10.1016/j.ctrv.2008.05.001 10.1016/j.ctrv.2008.05.001
17. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.Br J Cancer 2006,94(2):239–246. doi:10.1038/sj.bjc.6602920 10.1038/sj.bjc.6602920
18. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G: Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.Clin Cancer Res 1999,5(12):3914–3919.
19. Dougall WC, Holen I, Gonzalez Suarez E: Targeting RANKL in metastasis.Bonekey Rep 2014, 3:519. doi:10.1038/bonekey.2014.14
20. Drooger JC, van der Padt A, Sleijfer S, Jager A: Denosumab in breast cancer treatment.Eur J Pharmacol 2013,717(1–3):12–19. doi:10.1016/j.ejphar.2013.03.034
21. Fuller K, Bayley KE, Chambers TJ: Activin A is an essential cofactor for osteoclast induction.Biochem Biophys Res Commun 2000,268(1):2–7. doi:10.1006/bbrc.2000.2075 10.1006/bbrc.2000.2075
22. Garnero P: Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Mol Diagn Ther 2008,12(3):157–170. 10.1007/BF03256280
23. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer.Br J Cancer 2000,82(4):858–864. doi:10.1054/bjoc.1999.1012 10.1054/bjoc.1999.1012
24. Garnero P, Rousseau JC, Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases.Arthritis Rheum 2000,43(5):953–968. doi:10.1002/1529–0131(200005)43:5<953::AID-ANR1>3.0.CO;2-Q 10.1002/1529-0131(200005)43:5<953::AID-ANR1>3.0.CO;2-Q
25. Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD: Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.J Bone Miner Res 2003,18(10):1789–1794. doi:10.1359/jbmr.2003.18.10.1789 10.1359/jbmr.2003.18.10.1789
26. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI: Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.J Natl Cancer Inst 2013,105(9):654–663. doi:10.1093/jnci/djt026 10.1093/jnci/djt026
27. Gorai I, Taguchi Y, Chaki O, Nakayama M, Minaguchi H: Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover.Calcif Tissue Int 1997,60(4):317–322. 10.1007/s002239900235
28. Harris K, Li K, Flynn C, Chow E: Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases?Clin Oncol (R Coll Radiol) 2007,19(7):523–527. doi:10.1016/j.clon.2007.04.007 10.1016/j.clon.2007.04.007
29. Hortobagyi GN, Lipton A, Chew HK, Gradishar WJ, Sauter NP, Mohanlal RW, Zheng M, McGrain B, Van Poznak C: Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. In Oncologists ASoC (ed) 2014 ASCO Annual Meeting. Chicago, IL: vol 5S. Journal of Clinical Oncology, p LBA9500; 2014.
30. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vukosavljevic D: Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression.Eur J Cancer 2003,39(4):454–461. 10.1016/S0959-8049(02)00502-6
31. Kimmel DB: Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.J Dent Res 2007,86(11):1022–1033. 10.1177/154405910708601102
32. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.Clin Exp Metastasis 2006,23(2):117–122. doi:10.1007/s10585–006–9010–5 10.1007/s10585-006-9010-5
33. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R: Markers of bone resorption in patients treated with pamidronate.Eur J Cancer 1998,34(13):2021–2026. 10.1016/S0959-8049(98)00277-9
34. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.Cancer 2008,113(1):193–201. doi:10.1002/cncr.23529 10.1002/cncr.23529
35. Lipton A, Costa L, Coleman RE: Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?Breast Dis 2011,33(2):59–69. doi:10.3233/BD-2010–0327
36. Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R: Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.Clin Oncol (R Coll Radiol) 2013,25(4):217–226. doi:10.1016/j.clon.2012.11.004 10.1016/j.clon.2012.11.004
37. Mariotti A: Bisphosphonates and osteonecrosis of the jaws.J Dent Educ 2008,72(8):919–929.
38. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK).J Natl Cancer Inst 2005,97(16):1180–1184. 10.1093/jnci/dji237
39. Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere CJ, Christgau S: Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I.Calcif Tissue Int 2001,69(3):130–137. 10.1007/s002230020042
40. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di Blasio AM, Petraglia F: Serum and tissue expression of activin a in postmenopausal women with breast cancer.J Clin Endocrinol Metab 2002,87(5):2277–2282. 10.1210/jcem.87.5.8512
41. Risbridger GP, Schmitt JF, Robertson DM: Activins and inhibins in endocrine and other tumors.Endocr Rev 2001,22(6):836–858. 10.1210/edrv.22.6.0450
42. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL: Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.Calcif Tissue Int 1994,54(1):26–29. 10.1007/BF00316285
43. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T: Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort.Mod Rheumatol 2011,21(6):608–620. doi:10.1007/s10165–011–0455–2 10.3109/s10165-011-0455-2